
Tumor Mutational Burden Analysis
A TMB assay utilizing a whole exome sequencing (WES) of tumor specimens for reliable quantification of TMB across various tumor indications
Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio and is available for RUO or GCP applications.
Highlights:
- TMB assay available in two formats: tumor-only specimens or matched tumor and germline control blood specimens.
- Based on validated WES assay targeting ~60Mb of coding region of the human genome.
- TMB tumor-only WES method modeled across multiple tumor indications.
- High quantitative precision (CV% ≤20%) for TMB >2, suitable for TMB analysis across a wide range of cancer indications including those with traditionally low TMB.
IQVIA Laboratories TMB (WES)1 |
1.5 (N=123) |
2.4 (N=38) |
2.4 (N=100) |
4.6 (N=64) |
8.7 (N=39) |
10.1 (N=258) |
13.2 (N=113) |
Published TMB2 | 1.8 (N=220) |
2.5 (N=1456) |
2.7 (N=543) |
4.5 (N=7758) |
7.2 (N=80) |
9 (N=2102) |
14.4 (N=879) |
1 Median TMB scores generated from TCGA whole exome sequencing reads through our pipeline
2 Median TMB scores per Chalmers et al., Genome Medicine 2017
3 https://gdc.cancer.gov/about-data /publications/mc3-2017
LGG=Lower Grade Glioma, CHOL=Cholangiocarcinoma, KIRC=Renal Clear Cell Carcinoma, COAD=Colon Adenocarcinoma, BLCA=Urothelial Carcinoma, LUSC=Lung Squamous Cell Carcinoma,
SKCM=Cutaneous Melanoma, BRCA=Breast Invasive Carcinoma, HNSC=Head-Neck Squamous Cell Carcinoma, LUAD=Lung Adenocarcinoma, SKCM=Cutaneous Melanoma; STAD=Stomach Adenocarcinoma
TMB assay specifications |
|
---|---|
Sample Types | Tumor tissue (FFPE, fresh frozen or DNA specimens) Normal tissue, optional (PBMC, whole blood or DNA |
DNA Requirements | 250 ng DNA |
Assay Method | Whole Exome Sequencing |
System Compatibility | NovaSeq |
Assay Performance | >99.9% accuracy of variant calling for variants above 10% allelic frequency Quantitative precision ≤20% CV% across TMB range of 2-32 |
Deliverables | TMB score, FASTQ, BAM, annotated VCF files |
Immuno Assay Portfolio
Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio which includes other assays such as Immune Landscape Signature and Microsatellite Instability.

Related Services

Clinical Genomics Laboratory Services
Learn more
Oncomine Precision Assay on the Genexus System
Learn more
Single Cell RNA Sequencing
Learn more
Spatial Genomics
Learn more
TruSight Oncology 500 (TSO500)
Learn more